Emergent BioSolutions Stock Rises After New US Order For Smallpox Complication Therapy

Emergent BioSolutions shares rose after the company disclosed that it will supply additional doses of CNJ-016, a treatment used for certain complications of the smallpox vaccine, to the U.S. government.

The company’s shares closed 3.8% higher at $6.87 on Tuesday, with shares rising another 3.5% to $7.11 in after-hours trading.

The new shipment is part of a long-term deal signed back in 2019 with the Administration for Strategic Preparedness and Response, a branch of the Department of Health and Human Services. 

CNJ-016 is used to treat uncommon but serious side effects from the smallpox vaccine, such as eczema vaccinatum and progressive vaccinia. 

It is not intended for the treatment of postvaccinal encephalitis or isolated vaccinia keratitis. 

The product comes with several safety considerations, including risks of allergic reactions, kidney issues, blood clots, and inaccurate blood sugar readings in some patients due to interference with glucose monitors.

This latest modification comes shortly after a separate $62.4 million award on June 23, also from ASPR, for additional supply of Emergent’s botulism antitoxin, BAT. 

The BAT treatment is used in confirmed or suspected cases of botulism involving multiple neurotoxin types.

In a separate update last week, the company expanded its NARCANDirect platform to include Kloxxado Nasal Spray 8 mg, an opioid overdose reversal medication. 

The online ordering system is available to groups, including first responders, schools, government agencies, and community-based programs focused on naloxone distribution.

On Stocktwits, retail sentiment was ‘neutral’ amid ‘normal’ message volume.

Emergent BioSolutions’ stock has risen 33.1% so far in 2025.

For updates and corrections, email newsroom[at]stocktwits[dot]com.